Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs

References

• Lane RM, Baker GB. Chirality and drugs used in psychiatry: Nice to know or need to know? Cell Mol Neurobiol 1999; 19: 355–72.
   Google Scholar
• Calm RS, IngoId CK, Frelog V. The specification of asymmetric configuration in organic chemistry. Experientia 1966; 12: 81–124.
   Google Scholar
• Caldwell J, Wainer IW. Stereochemistry: definitions and a note on nomenclature. Human Psycho pharmacol Clin Exp 2001; 16: S105–7.
   Web of Science ®Google Scholar
• Coutts RT, Baker GB. Implications of chirality and geometric isomerism in some psychoactive drugs and their metabolites. Chirality 1989; 1: 99–120.
   PubMed Web of Science ®Google Scholar
• Evans AM, Nation RH, Sansom LN, Bochner F, Somogyi AA. Stereoselective drug disposition: Potential for misinterpretation of drug disposition data. Br J Clin Pharmacol 1988; 26: 771–80.
   PubMedGoogle Scholar
• Lee EJD, Williams KM. Chirality: Clinical pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 1990; 18: 339–45.
   PubMed Web of Science ®Google Scholar
• Tucker GT,Lennard MA. Enantiomer specific pharmaco-kinetics. Pharmacol T her 1990; 45: 309–29.
   PubMedGoogle Scholar
• Campbell DB. Selectivity in clinical pharmacokinetcs and drug development. Eur J Drug Metab Pharmacokinet 1990; 15: 109–25.
   PubMedGoogle Scholar
• Evans AM. Enantioselective pharmacodynamics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1992; 42: 237–56.
   PubMed Web of Science ®Google Scholar
• Gibaldi M. Stereoselective and isozyme-selective drug inter-actions. Chirality 1993; 5: 407–13.
   PubMed Web of Science ®Google Scholar
• Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 2001; 4: 185–200.
   PubMed Web of Science ®Google Scholar
• Caldwell J. Do single enantiomers have something special to offer? Human Psychopharmacol Clin Exp 2001; 16: S67–71.
   PubMed Web of Science ®Google Scholar
• Wainer 1W. The therapeutic promise of single enantiomers: introduction. Human Psychopharmacol Clin Exp 2001; 16: S73–7.
   Google Scholar
• Baumann P, Eap CB. Enantiomeric antidepressant drugs should be considered on individual merit. Human Psychopharmacol Clin Exp 2001; 16: S85–92.
   PubMed Web of Science ®Google Scholar
• Leonard BE. An introduction to enantiomers in psychopharmacology. Human Psychopharmacol Clin Exp 2001; 16: S79–84.
   Google Scholar
• Hindmarch I. The enantiomer debate: current status and future directions. Human P sychoph armacol Clin Exp 2001; 16: S101–4.
   Google Scholar
• Baldwin DS. Unmet needs in the pharmacological management of depression. Human Psychopharmacol Clin Exp 2001; 16: S93–9.
   Google Scholar
• Hyneck M, Dent J, Hook J. Chirality: Pharmacological action and drug development. In: Brown C., ed. Chirality in Drug Design and Synthesis. London: U.K. Academic Press; 1990: 1–28.
   Google Scholar
• Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci 1989; 78: 695–715.
   PubMed Web of Science ®Google Scholar
• Caldwell J. Importance of stereospecific bioanalytical mon-itoring in drug development. J Chromatogr A 1996; 719: 3–13.
   PubMed Web of Science ®Google Scholar
• Tucker GJ. Chiral switches. Lancet 2000; 355: 1085–7.
   PubMedGoogle Scholar
• Gross G, Xin S, Gastpar M. Trimipramine: Pharmacological reevaluation and comparison with clozapine. Neuropharma-cology 1991; 30: 1159–66.
   PubMed Web of Science ®Google Scholar
• Baumann P. Clinical pharmacokinetics of citalopram and other selective serotonergic reuptake inhibitors (SSRI). Int Clin Psychopharmacol 1992; 6: 13–20.
   PubMedGoogle Scholar
• Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci 1995; 57: 411–41.
   Google Scholar
• Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropsychopharmacology 1992; 31: 997–1000.
   Google Scholar
• Potts BD, Parli CJ. Analysis of the enantiomers of fluoxetine and norfluoxetine in plasma and tissue using chiral derivatiza-tion and normal-phase liquid chromatography. J Liq Chromatogr 1992; 15: 665–81.
   Web of Science ®Google Scholar
• Torok-Both GA, Baker GB, Coutts RT, McKenna KF, Aspeslet L J. Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron capture detection. J Chromatogr 1992; 579: 99–106.
   PubMed Web of Science ®Google Scholar
• Eap CB, Gaillard N, Powell, K, Bauman P. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chroma-tography-mass spectrometry. J Chromatogr 1996; 682: 265–72.
   Google Scholar
• Pichini S, Paafici R,Altieri I, Pellegrini M,Zuccaro P. Stereoselective determination of fluoxetine and norfluoxetine enantiomers in plasma samples by high pressure liquid chromatography. J Liq Chromatogr Rel Technol 1996; 19: 1927–35.
   Web of Science ®Google Scholar
• Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay, K, Kosel M, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 2001; 21: 330–4.
   PubMed Web of Science ®Google Scholar
• Stevens, JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993; 266: 964–71.
   PubMed Web of Science ®Google Scholar
• Agranat I, Caner H. Intellectual property and chirality of drugs. Drug Discov Today 1999; 4: 313–21.
   PubMed Web of Science ®Google Scholar
• Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram resides in the 5-(+) enantiomer. J Neural Trans 1992; 88: 157–60.
   PubMed Web of Science ®Google Scholar
• Kelsey JE, Nemeroff CB. Citalopram. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, seventh ed. Philadelphia.. Lippincott Williams & Wilkins; 1999: 2435–8.
   Google Scholar
• Rochat B, Amery M, Bauman P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monitor 1995; 17: 273–9.
   Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–6.
   PubMed Web of Science ®Google Scholar
• Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95–102.
   PubMed Web of Science ®Google Scholar
• Horn AS, Snyder SH. Steric requirements for catecholamine uptake by rat brain synaptosomes: Studies with rigid analogs of amphetamine. J Pharmacol Exp Ther 1972; 180: 523–30.
   PubMed Web of Science ®Google Scholar
• Fuentes JA, Oleshansky MA, Neff NH. Comparison of the apparent antidepressant activity of (+)- and (- )-tranylcypramine in an animal model. Biochem Pharmacol 1976; 25: 801–4.
   PubMedGoogle Scholar
• Hampson DR, Baker GB, Coutts RT. A comparison of the neurochemical properties of the stereoisomers of tranylcypromine in the central nervous system. Cell Mol Biol 1986; 32: 593–9.
   PubMed Web of Science ®Google Scholar
• Nicholson VJ, Pinder RM. In: Smith DE (ed.) Handbook of Stereoisomers: Drugs in Psychopharmacology. Boca Raton: CRC Press, 1984: 215–40.
   Google Scholar
• Repchinsky C, ed. Compendium of Pharmaceuticals and Specialties (CPS). Ottawa: Canadian Pharmacists Association; 2002: 1855–8.
   Google Scholar
• Schoemaker H, Berendsen HH, Stevens HJ, Nidcolson VJ Differences in presynaptic alpha-blockade, noradrenaline uptake inhibition, and potential antidepressant activity between (+)- and (-)-mianserin. Psychopharmacology (Berl) 1981; 74: 137–42.
   PubMedGoogle Scholar
• Raiteri M, Maura G, Versace P. Functional evidence for two stereochemically different alpha-2 adrenoceptors regulating central norephinephrine and serotonin release. J Pharmacol Exp Ther 1983; 224: 679–84.
   PubMed Web of Science ®Google Scholar
• Wood MD, Thomas DR, Watkins CJ, Newberry Nit. Stereoselective interaction of mianserin with 5-HT3 receptors. J Pharm Pharmacol 1993; 45: 711–4.
   PubMedGoogle Scholar
• Kooyman AR, Swart R, Vanderheijden PM, Van-Hooft JNA, Vijverberg HP. Interaction between enantiomers of mianserin and 0RG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells. Neuro pharmacology 1994; 33: 501–7.
   Google Scholar
• Heinig R, Blaschke G. In vivo and in vitro stereoselective metabolism of mianserin in mice. Arzneimittelforschung 1993; 43: 5–10.
   PubMedGoogle Scholar
• Dahl ML, Tybring G, Elwin CE, Andreasson K, Gyllenpalm M, Berfilsson L. Stereoselective disposition of mianserin is related to debrisoquine hydoxylation. Clin Pharmacol Ther 1994; 56: 176–83.
   PubMed Web of Science ®Google Scholar
• Tybring G, Otani, K, Kaneko S, Mihara K, Fukushima, Bertilsson L. Enantioselective determination of mianserin and its desmethyl metabolite in plasma during treatment of depressed Japanese patients. Ther Drug Monit 1995; 17: 516–21.
   Google Scholar
• Eap CB, Powell K, Campussouche D, Monney C, Baettig D, Taesclmer W, et al. Determination of the enantiomers of mianserin, desmethylmianserin, and 8-hydroxymianserin in the plasma and urine of mainserin-treated patients. Chirality 1994; 6: 555–63.
   PubMedGoogle Scholar
• Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselec-rive metabolism of mainserin enantiomers. J Pharmacol Exp Ther 1996; 278: 21–30.
   PubMed Web of Science ®Google Scholar
• Mendlewicz J. Pharmacologic profile and efficacy of venla-faxine. Int Clin Psycho pharmacol 1995; 2: 5–13.
   Google Scholar
• Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149–56.
   PubMed Web of Science ®Google Scholar
• Claghorn JL. Mirtazapine. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, seventh ed. Philadelphia: Lippincott Williams 8c Wilkins; 1999: 2390–7.
   Google Scholar
• Dodd S, Burrows GD, Norman TR. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. J Chromatogr 2000; 748: 439–43.
   Google Scholar
• Svendsson CN, Friomowitz M, Hrbek C, Campbell A, Kula N, Baldessarini RJ, Cohan BM, Teicher MH, Bird ED. Receptor affinity, neurochemistry and behavioural characteristics of the enantiomers of thioridazine: Evidence for different stereoselectivities at Di and D2 receptors in rat brain. Neuro pharmacology 1988; 27: 1117–24.
   Google Scholar
• Kaiser C, Seder PE. Antipsychotic agents. In: Wolff ME (ed.), Burger's Medicinal Chemistry, Part III, 4th ed., New York: John Wiley and Sons, 1981: 859.
   Google Scholar
• Jortani SA, Poklis A. Determination of thioridazine enantio-mers in human serum by sequential achiral and chiral high-performance liquid chromatography. J Anal Toxicol 1993; 17: 374–7.
   PubMedGoogle Scholar
• von Bahr C, Movin G, Nordin C, Liden A. Hammarlund-Udenaes M, Hedberg A, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxyl-ation phenotype. Clin Pharmacol T her 1991; 49: 234–9.
   PubMedGoogle Scholar
• Brosen K. Recent developments in hepatic drug oxidation (implications for clinical pharmacokinetics). Clin Pharmaco-kinet 1990; 18: 220–39.
   PubMed Web of Science ®Google Scholar
• Eap CB, Cuentert TW, Schaublin Loidl M, Stabl M, Koeb L, Powell K, et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone and thioridazine 5-sulfoxide in poor and extensive metab-olizers of dextromethorphan and mephenytoin. Clin Pharma-col T her 1996; 59: 322–33.
   PubMed Web of Science ®Google Scholar
• Boireau A, Blanchard J-C, Garret C, Julou L. The use of thioproperazine, a phenothiazine derivative, as a ligand for neuroleptic receptors. II. In vivo studies. Biochem Pharmacol 1980; 29: 2339.
   PubMedGoogle Scholar
• Muller MJ, Hartter S, Kohler D, Hiemke Ch. Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: A pilot study. Pharmacopsy-chiatry 2001; 34: 27–32.
   PubMed Web of Science ®Google Scholar
• Yashui-Furukori, N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G. Different enantioselective 9-hydroxy-lation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001; 29: 1263–8.
   PubMedGoogle Scholar
• Shin J-G, Kane K, Flockhart DA. Potent inhibition of CYP2D6 by reduced haloperidol metabolites: Stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol 2001; 5: 45–52.
   Google Scholar